Report date: July 30, 2026
Event: 2026 Q2 earnings call
Closing share price on July 29: $1,388.79
MTD’s second-quarter numbers matter, but the credibility of management’s expected second-half acceleration will probably determine the stock reaction.
Management entered Q2 expecting approximately 3% local-currency sales growth, including roughly 1.5 percentage points from acquisitions, and adjusted EPS of $10.70–$10.85. That is not an especially demanding organic-growth target. The larger question is whether improving pipelines, China industrial demand, bioprocessing and product-inspection strength can produce the faster growth embedded in the full-year outlook.
The stock has already recovered roughly 35% from its May low and trades at approximately 29.8 times the midpoint of management’s 2026 adjusted EPS guidance. Consequently, an in-line quarter accompanied by cautious Q3 commentary may not be sufficient.
| Metric | Q2 2026 management outlook / benchmark | Q2 2025 |
|---|---|---|
| Local-currency sales growth | Approximately 3% | 2% |
| Acquisition contribution | Approximately 1.5 pts | Not material |
| Implied organic local-currency growth | Approximately 1.5% | Approximately 2% |
| Expected FX contribution to reported sales | Approximately 2 pts | — |
| Implied reported revenue | Approximately $1.03 billion | $983.2 million |
| Adjusted EPS | $10.70–$10.85 | $10.09 |
| Adjusted EPS growth | 6%–8% | 5% |
| Prior-year adjusted operating margin | Key comparison: 28.8% | 28.8% |
Q1 local-currency sales grew 3%, but acquisitions contributed approximately 1.5 points, leaving only about 1% organic growth. Q2 guidance implies a similarly modest organic result.
Maintaining approximately 4% local-currency growth for the full year therefore requires a clear acceleration during the second half—roughly toward the mid-single digits, depending on acquisition and currency effects. The EPS outlook is similarly back-end weighted: after Q1 actual EPS and the Q2 guidance range, MTD would need approximately $26.54–$27.34 of adjusted EPS in the second half, versus $24.51 in the second half of 2025.
Management has argued that this acceleration is supported by:
Investors should focus less on general statements that the pipeline is “strong” and more on whether management can identify actual order conversion, improving close rates or better exit trends during June and July.
Laboratory represented approximately 55% of Q1 sales but grew only 1% in local currency and was flat organically. Pipettes remained weak because of soft academic and biotech demand, while chemical and small-molecule pharmaceutical customers were cautious.
Positive areas included bioprocessing, process analytics and demand associated with new manufacturing capacity, including GLP-1 investments.
For Q2, management expected Laboratory to grow in the low- to mid-single digits in local currency, but only low single digits organically. A constructive report would show:
A second consecutive quarter of flat or declining organic Laboratory sales would raise doubts about the full-year growth assumptions.
Core Industrial was flat organically in Q1. Management nevertheless expects it to be one of the primary drivers of the second-half acceleration.
China has been the bright spot. Chinese Industrial sales grew at a high-single-digit rate in Q1, benefiting from factory automation, digitalization, batteries and other advanced-manufacturing investments. Western markets were weaker, particularly chemical customers affected by higher energy costs and broader uncertainty.
The critical questions are:
A strong China result without improvement in Western markets may support the quarter but leave the second-half outlook vulnerable.
Product Inspection grew 11% in local currency and 6% organically in Q1. MTD is gaining traction from its expanded mid-market portfolio, new metal-detection products and higher-end X-ray systems.
Management cautioned that Q2 growth would slow because of project timing following a strong Q1, especially in the Americas. Therefore, moderate Q2 growth would not necessarily indicate deteriorating fundamentals. Investors should instead assess:
Service revenue grew 7% in local currency and 5% organically in Q1. It remains one of MTD’s most attractive growth vectors because of its recurring characteristics, installed-base opportunity and customer-retention benefits.
Organic service growth around the mid-single digits or better would help offset product volatility and strengthen the quality of the revenue mix. Material slowing would be a negative signal regarding customer utilization or discretionary maintenance spending.
Q1 adjusted operating margin declined 80 basis points to 26.0%, although management said it expanded 40 basis points excluding currency. Incremental tariffs represented a roughly 90-basis-point margin headwind and a 4% gross headwind to adjusted EPS.
Q2 will test whether MTD’s pricing and productivity programs can offset:
Management expected approximately 2.5% pricing in Q2, stepping down toward a normalized 2% in the second half. Pricing above 2.5%, without an apparent volume penalty, would be encouraging.
Investors should also separate operating performance from below-the-line support. Q1 adjusted EPS grew 9% while adjusted operating profit increased only 4%, helped by lower share count and favorable below-the-line items. MTD’s buybacks are valuable, but a premium valuation is easier to defend if earnings growth also reflects organic sales and margin expansion.
The most important new data point may be Q3 guidance. MTD generated $11.15 of adjusted EPS and 6% local-currency sales growth in Q3 2025, creating a reasonably demanding comparison.
At $1,388.79, MTD is approximately flat versus the beginning of 2026, but the path has been volatile. The shares fell sharply following the Q1 report, reaching roughly $1,026 in May, before recovering to current levels.
At about 29.8 times the midpoint of the $46.30–$46.95 adjusted EPS range, the market is again assigning considerable value to MTD’s quality, pricing power, recurring service revenue, share gains and long-term automation exposure. The valuation also means investors are unlikely to tolerate another reduction in the underlying organic-growth outlook.
This outcome could produce a relatively muted reaction because the stock has already recovered substantially.
The formal Q2 bar—approximately 3% local-currency growth and $10.70–$10.85 of adjusted EPS—appears achievable. The harder test is whether MTD can demonstrate that the first half represented a temporary period of delayed customer spending rather than a more persistent low-growth environment.
The best outcome would combine an above-guidance quarter with concrete evidence of improving order conversion in Western Industrial and Laboratory markets. Conversely, an EPS beat driven mainly by buybacks or below-the-line items, accompanied by another cautious sales outlook, would be lower quality and could be poorly received at the current valuation.
Research based on MTD’s 2026 Q1 earnings release, earnings-call transcript and Form 10-Q; its 2025 Q2–Q4 earnings releases; recent company-specific news; and stock prices through July 29, 2026.